Skip to main content
. 2011 May 1;3(3):273–288. doi: 10.4161/mabs.3.3.15188

Figure 7.

Figure 7

In vivo superior efficacy of EI-04 in two xenograft models. (A) Efficacy of EI-04 at 20 mg/kg in comparison to M60-A02 or C06 dosed at 15 mg/kg as single agents or in combination in the BxPC3 pancreatic cancer model. (B) Efficacy of EI-04 at 20 mg/kg, 10 mg/kg and 5 mg/kg in comparison to the M60-A02/C06 combination dosed at 15 + 15 mg/kg, 7.5 + 7.5 mg/kg and 3.75 + 3.75 mg/kg in the BxPC3 pancreatic cancer model. (C) Efficacy of EI-04 at 20 mg/kg in comparison to M60-A02 or C06 dosed at 15 mg/kg as single agents or in combination in the GEO colon cancer model. Tumor-bearing mice were given intraperitoneal administration of a control IgG (ctrl Ab, 5C8), M60-A02 and EI-04 twice a week (BIW) or C06 once a week (QW). The dosing schedules are indicated on the x-axis. The mean tumor volumes from each treatment group of approximately 10 mice were plotted as a function of time. The differences in the tumor growth rate between the mAb treatment groups and the EI-04 group dosed at the equal molar doses were indicated by *p < 0.05, **p < 0.01 or ***p < 0.001, if they are statistically significant as determined by one-way ANOVA.